Trial Profile
A study assessing the severe hypoxemia and cytokine storm, clinical status and pulmonary failure with treatment with Baricitinib in Patients with Severe Pneumonia due to COVID-19 in Veracruz, Mexico
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Feb 2022
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications COVID-19 pneumonia; Cytokine release syndrome; Hypoxaemia
- Focus Therapeutic Use
- 05 Feb 2022 New trial record